Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Jun 3 2019 Oramed to Present at BIO International Convention
- May 21 2019 Oramed Completes Patient Recruitment of Phase IIb HbA1c Trial for Oral Insulin Capsule ORMD-0801
- Apr 29 2019 Oramed to Present at ThinkEquity Conference
- Apr 11 2019 Oramed to Present at 3rd Annual Clinical Trials Summit
- Apr 4 2019 Oramed Patent Allowed in the U.S. for Oral Exenatide